sellWeak cluster of 5
Robert Renninger sold $850 of LONA
SVP, Finance and Accounting at Athira Pharma, Inc.. 2,897 shares at an average of $0.29, traded Jul 1, 2025, filed Jul 2, 2025.
Warning score
15Value
$850
2,897 shares
Holdings after
109,186
-3% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- 0Trade size$850 at market
- 0Share of holdings soldSold 2.6% of holdings
- +15Cluster5 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001415889-25-019064, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 19, 2025 | AGrant or award Common Stock | +10,000 | $0.23 | $2,312 | 99,724 | Jul 2, 2025 |
| Jun 30, 2025 | MOption exercise Common Stock | +12,359 | $0.00 | $0 | 112,083 | Jul 2, 2025 |
| Jul 1, 2025 | SOpen-market sale Common Stock | -2,897 | $0.29 | $850 | 109,186 | Jul 2, 2025 |
| Jun 30, 2025 | MOption exercise Restricted Stock Unitsderivative | -12,359 | $0.00 | $0 | 12,359 | Jul 2, 2025 |
Related signals
Other insiders at Athira Pharma, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | Athira Pharma, Inc. | Mark Worthington General Counsel and CCO | $2,502 8,526 shares | -7% | |
| 20Weak | Athira Pharma, Inc. | Martin Javier San CHIEF MEDICAL OFFICER | $3,182 10,842 shares | -13% | |
| 25Weak | Athira Pharma, Inc. | Mark James Litton President and CEO | $7,374 25,123 shares | -7% | |
| 15Weak | Athira Pharma, Inc. | Church Kevin CHIEF SCIENTIFIC OFFICER | $2,502 8,526 shares | -5% | |
| 15Weak | Athira Pharma, Inc. | Mark Worthington General Counsel and CCO | $4,782 8,510 shares | -9% | |
| 15Weak | Athira Pharma, Inc. | Robert Renninger VP of Finance | $1,619 2,881 shares | -3% | |
| 15Weak | Athira Pharma, Inc. | Church Kevin CHIEF SCIENTIFIC OFFICER | $4,782 8,510 shares | -6% | |
| 25Weak | Athira Pharma, Inc. | Mark James Litton President and CEO | $14k 25,107 shares | -9% | |
| 20Weak | Athira Pharma, Inc. | Martin Javier San CHIEF MEDICAL OFFICER | $6,083 10,826 shares | -23% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.